 |
Business strategy |
To build significant company value, we will focus on establishing clinical proof-of-concept of our prime product candidate Vvax001 in a first indication.
We will broaden our IPR position by establishing research collaborations with the University of Groningen on new applications of SFV based immunotherapy. Along the way we will establish partnerships with other cancer vaccine initiatives and companies.
Ultimately we aim to generate revenues on licensing fees coming from milestone payments and royalties on sales, following the success of our partners.
Our exit strategy will most likely be a trade sale to a strategic partner. |
| |
|
|
